Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial

BACKGROUND: Hypofractionated palliative radiotherapy for metastatic lung cancer patients is frequently used in order to ease pain, to increase bone stability, to treat local mass effects, or to prolong progression-free survival at critical sites. Recently introduced, immunotherapy for patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Bozorgmehr, Farastuk, Hommertgen, Adriane, Krisam, Johannes, Lasitschka, Felix, Kuon, Jonas, Maenz, Martin, Huber, Peter E., König, Laila, Kieser, Meinhard, Debus, Juergen, Thomas, Michael, Rieken, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842256/
https://www.ncbi.nlm.nih.gov/pubmed/31703637
http://dx.doi.org/10.1186/s12885-019-6205-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842256/
https://www.ncbi.nlm.nih.gov/pubmed/31703637
http://dx.doi.org/10.1186/s12885-019-6205-0

Ejemplares similares